Automate Your Wheel Strategy on PFE
With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Published: March 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Pfizer (PFE) Down 0.6% Since Last Earnings Report: Can It Rebound?
Published: March 05, 2026 by: Zacks Investment Research
Sentiment: Negative
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock?
Read More
Can Pfizer Reignite Growth Amid COVID Declines and Patent Expirations?
Published: March 05, 2026 by: Zacks Investment Research
Sentiment: Positive
PFE faces falling COVID sales, looming patent cliffs and IRA pressure. It is betting on cost cuts, new launches and pipeline rebuilds to revive growth.
Read More
Forget Teva: This Dividend Top Dog Is the Real Value Buy Today
Published: March 04, 2026 by: The Motley Fool
Sentiment: Positive
Teva Pharmaceutical is a bit of a turnaround story, as the company continues a major business overhaul. This competitor, with a huge 6.3% yield, has hit a few setbacks, but it is still just business as usual.
Read More
Seven S&P500 Ideal 'Safer' March Dividend Dogs
Published: March 04, 2026 by: Seeking Alpha
Sentiment: Positive
Seven S&P 500 dividend 'Dogs'—including VICI, VZ, BEN, F, HST, T, and KEY—offer high yields supported by sufficient free cash flow, making them attractive buys. Analyst forecasts project 14.2% to 32.2% net gains for the top ten S&P 500 dividend stocks by March 2027, with an average estimated gain of 20.51%. Dividend safety is emphasized: only stocks with positive free cash flow margins and yields from $1K invested exceeding share prices are considered 'safer' and ideal for purchase.
Read More
Pfizer's Portfolio Renewal In Progress - High Yields For The Patient
Published: March 04, 2026 by: Seeking Alpha
Sentiment: Positive
Pfizer's portfolio renewal is in progress, with new launches and acquisitions driving +14.6% YoY growth in new product revenues, though legacy drug expiries may pressure intermediate-term sales. These developments lend credence to their frenzied M&A/licensing activities despite the potential debt risks, given the reasonable, estimated net interest coverage ratio of 6.91x. Their R&D efforts are still reasonable at ~16.6% of their top lines in FY2025, near their 5Y pre-pandemic averages of ~16.3%, with it presenting the sector's capital-intensive R&D/M&A thesis.
Read More
Pfizer's Quiet Cash Comeback
Published: March 03, 2026 by: Seeking Alpha
Sentiment: Positive
Pfizer delivers a 75.81% gross margin and 41.05% EBITDA margin, dramatically outperforming sector medians of 59.35% and 10.40%. Management targets $1.3 billion in net cost savings by 2026, reinforcing structural margin durability despite revenue pressure. Trailing operating cash flow reached $13.08 billion, fully covering $9.8 billion in dividends with a 6.22% yield.
Read More
Pfizer Inc. (PFE) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Published: March 02, 2026 by: Seeking Alpha
Sentiment: Neutral
Pfizer Inc. (PFE) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Read More
Pfizer Stock: Buy, Sell or Hold After Its 11% Rally So Far in 2026?
Published: March 02, 2026 by: Zacks Investment Research
Sentiment: Neutral
Pfizer's PFE stock has risen 11% so far in 2026. The stock has also been consistently trading above its 50-day and 200-day simple moving averages (SMAs) since early January.
Read More
Pfizer CEO flags issues with FDA's vaccine leadership
Published: March 02, 2026 by: Reuters
Sentiment: Negative
Pfizer CEO Albert Bourla on Monday flagged issues with the leadership of the U.S. Food and Drug Administration's vaccine department.
Read More
PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
Published: February 27, 2026 by: Business Wire
Sentiment: Neutral
NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced positive results from the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for PADCEVTM (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda® (pembrolizumab), a PD-1 inhibitor, in patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy. Perioperative.
Read More
My 5 Favorite Dividend Stocks to Buy Right Now
Published: February 22, 2026 by: The Motley Fool
Sentiment: Positive
It may be the right time for investors to start playing a little less offense and a little more defense. The best defensive names, however, are shares of businesses that continue to generate cash flow regardless of the economic environment.
Read More
AstraZeneca vs. Pfizer: Which Pharma Giant Has the Edge in 2026?
Published: February 20, 2026 by: Zacks Investment Research
Sentiment: Positive
AZN's stronger growth outlook and 2030 revenue target may outshine PFE's yield and cheaper valuation.
Read More
Pfizer Targets Long-Term Oncology Growth Amid Competitive Pressure
Published: February 19, 2026 by: Zacks Investment Research
Sentiment: Negative
PFE's oncology sales rose 8% in 2025 as Padcev, Lorbrena and new launches offset Ibrance declines.
Read More
Top High-Yield Stocks to Double Up on Right Now
Published: February 19, 2026 by: The Motley Fool
Sentiment: Positive
Pfizer has made the investments needed to get its drug pipeline back on track. United Parcel Service's turnaround effort is starting to show progress.
Read More
Is There 25% Downside For Pfizer Stock?
Published: February 18, 2026 by: Forbes
Sentiment: Negative
Our comprehensive evaluation suggests that divesting from Pfizer stock (NYSE: PFE) may be the most prudent course of action. Our analysis points a bearish outlook on the stock, with a plausible price target of $20.
Read More
Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game
Published: February 18, 2026 by: Seeking Alpha
Sentiment: Positive
Despite the recent recovery, I explain why Pfizer remains materially undervalued, trading near 10-year lows with a 6.4% dividend yield. Pfizer faces multi-year headwinds from loss of exclusivity and COVID franchise decline, but management highlights transformative M&A and pipeline optionality. Obesity drugs, particularly via Metsera, represent a potential $150B TAM, though market skepticism persists until Phase III data matures.
Read More
Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund
Published: February 10, 2026 by: Reuters
Sentiment: Neutral
Pfizer agreed to accept $29 million to resolve a dispute with the U.S. Securities and Exchange Commission stemming from the regulator's 2013 insider trading settlement with billionaire Steven A. Cohen's former hedge fund SAC Capital Management.
Read More
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Published: February 10, 2026 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Should You Buy, Sell or Hold Pfizer Stock After a Lukewarm Q4?
Published: February 09, 2026 by: Zacks Investment Research
Sentiment: Positive
PFE beat Q4 estimates, but weak COVID sales and soft 2026 guidance kept shares muted as investors weigh pipeline strength against looming headwinds.
Read More
3 High-Yield Dividend Stocks Perfect For Retirees
Published: February 06, 2026 by: 24/7 Wall Street
Sentiment: Positive
What does a successful retirement look like? If it means financial security through steady income sources, then you can get there with the help of high-yield dividend stocks.
Read More
Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data
Published: February 06, 2026 by: CNBC
Sentiment: Positive
Pfizer made one thing clear this week: It's officially back in the obesity race.
Read More
Pfizer Bets Big on Obesity and Oncology With 2026 Pipeline Push
Published: February 06, 2026 by: Zacks Investment Research
Sentiment: Neutral
PFE is betting on obesity and oncology in 2026, lining up 20 pivotal studies after $9B in 2025 M&A.
Read More
Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026
Published: February 04, 2026 by: The Motley Fool
Sentiment: Positive
Eli Lilly has leading products in the GLP-1 space, with plans to bring pill versions of its weight loss shots to market. Pfizer is playing catch-up in the GLP-1 space, but it has a long history of innovation.
Read More
Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript
Published: February 03, 2026 by: Seeking Alpha
Sentiment: Neutral
Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript
Read More
Pfizer: Messy Q4 Earnings Mask An Improving Business
Published: February 03, 2026 by: Seeking Alpha
Sentiment: Positive
Pfizer Inc. earns a Buy rating as the market overreacts to Q4's non-cash loss and conservative 2026 guidance, overlooking underlying operational strength. Excluding COVID-19 products, PFE posted 9% YoY growth, driven by oncology, signaling a successful pivot away from declining pandemic franchises. Patent cliffs—Xeljanz in 2026, Eliquis in 2028—pose risks, but PFE is aggressively advancing a 102-candidate pipeline targeting oncology, obesity, and migraine.
Read More
Pfizer Stock Slides Despite Q4 Earnings Beat and New Obesity Drug Data
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Negative
PFE shares fall even after Q4 earnings beat on COVID product declines and muted investor reaction to new obesity drug data.
Read More
Silver Surges Over 15%; Pfizer Earnings Top Views
Published: February 03, 2026 by: Benzinga
Sentiment: Neutral
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Tuesday.
Read More
Pfizer Q4 Earnings Review: This Classic Value Trap Remains As Tempting As Ever
Published: February 03, 2026 by: Seeking Alpha
Sentiment: Negative
Pfizer reported Q4 and FY2025 revenues and EPS above expectations, but core revenues declined due to falling COVID product sales. Despite a 6.5% dividend yield and low valuation multiples, PFE remains a value trap as share price performance lags and patent expiries loom. Recent M&A, including Seagen and Metsera, must deliver as COVID windfall fades and major assets like Eliquis and Prevnar approach patent cliffs.
Read More
Pfizer, Merk report Q4 results: Citi's Geoff Meacham on key takeaways
Published: February 03, 2026 by: CNBC Television
Sentiment: Neutral
Geoff Meacham, Citi Research head of U.S. pharmaceuticals and biotechnology, joins 'Squawk Box' to break down the quarterly earnings results of Pfizer and Merck.
Read More
About Pfizer Inc. (PFE)
- IPO Date 1972-06-01
- Website https://www.pfizer.com
- Industry Drug Manufacturers - General
- CEO Albert Bourla
- Employees 81000